BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Davis LS, Reimold AM. Research and therapeutics-traditional and emerging therapies in systemic lupus erythematosus. Rheumatology (Oxford). 2017;56:i100-i113. [PMID: 28375452 DOI: 10.1093/rheumatology/kew417] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Grygiel-Górniak B. Antimalarial drugs-are they beneficial in rheumatic and viral diseases?-considerations in COVID-19 pandemic. Clin Rheumatol 2021. [PMID: 34218393 DOI: 10.1007/s10067-021-05805-5] [Reference Citation Analysis]
2 Miyazaki C, Sruamsiri R, Mahlich J, Jung W. Treatment patterns and medical cost of systemic lupus erythematosus patients in Japan: a retrospective claims database study. J Med Econ 2020;23:786-99. [PMID: 32149541 DOI: 10.1080/13696998.2020.1740236] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
3 de Silva NL, Seneviratne SL. Haemopoietic stem cell transplantation in Systemic lupus erythematosus: a systematic review. Allergy Asthma Clin Immunol 2019;15:59. [PMID: 31548842 DOI: 10.1186/s13223-019-0373-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
4 Liu E, Perl A. Pathogenesis and treatment of autoimmune rheumatic diseases. Curr Opin Rheumatol 2019;31:307-15. [PMID: 30920455 DOI: 10.1097/BOR.0000000000000594] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 7.5] [Reference Citation Analysis]
5 Ramirez GA, Coletto LA, Bozzolo EP, Citterio L, Delli Carpini S, Zagato L, Rovere-Querini P, Lanzani C, Manunta P, Manfredi AA, Sciorati C. The TRPC6 intronic polymorphism, associated with the risk of neurological disorders in systemic lupus erythematous, influences immune cell function. J Neuroimmunol 2018;325:43-53. [PMID: 30384327 DOI: 10.1016/j.jneuroim.2018.10.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
6 Mu X, Wang C. Artemisinins—a Promising New Treatment for Systemic Lupus Erythematosus: a Descriptive Review. Curr Rheumatol Rep 2018;20. [DOI: 10.1007/s11926-018-0764-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
7 Cui M, Li T, Yan X, Wang C, Shen Q, Ren H, Li L, Zhang R. Blood Genomics Identifies Three Subtypes of Systemic Lupus Erythematosus: "IFN-High," "NE-High," and "Mixed". Mediators Inflamm 2021;2021:6660164. [PMID: 34305454 DOI: 10.1155/2021/6660164] [Reference Citation Analysis]
8 Foster MH, Ord JR. Emerging immunotherapies for autoimmune kidney disease. Hum Vaccin Immunother 2019;15:876-90. [PMID: 30550361 DOI: 10.1080/21645515.2018.1555569] [Reference Citation Analysis]
9 Tocut M, Shoenfeld Y, Zandman-Goddard G. Systemic lupus erythematosus: an expert insight into emerging therapy agents in preclinical and early clinical development. Expert Opin Investig Drugs 2020;29:1151-62. [PMID: 32755494 DOI: 10.1080/13543784.2020.1807004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
10 Wu H, Jia B, Zhao X, Zhang H, Li Z, Wang W, Chen X, Zhang S. Pathophysiology and system biology of rat c-BSA induced immune complex glomerulonephritis and pathway comparison with human gene sequencing data. Int Immunopharmacol 2022;109:108891. [PMID: 35691274 DOI: 10.1016/j.intimp.2022.108891] [Reference Citation Analysis]
11 Pacheco Y, Barahona-Correa J, Monsalve DM, Acosta-Ampudia Y, Rojas M, Rodríguez Y, Saavedra J, Rodríguez-Jiménez M, Mantilla RD, Ramírez-Santana C, Molano-González N, Anaya JM. Cytokine and autoantibody clusters interaction in systemic lupus erythematosus. J Transl Med 2017;15:239. [PMID: 29178890 DOI: 10.1186/s12967-017-1345-y] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 5.4] [Reference Citation Analysis]
12 Liu Y, Tao X, Tao J. Strategies of Targeting Inflammasome in the Treatment of Systemic Lupus Erythematosus. Front Immunol 2022;13:894847. [PMID: 35664004 DOI: 10.3389/fimmu.2022.894847] [Reference Citation Analysis]
13 Yan S, Wang W, Gao G, Cheng M, Wang X, Wang Z, Ma X, Chai C, Xu D. Key genes and functional coexpression modules involved in the pathogenesis of systemic lupus erythematosus. J Cell Physiol 2018;233:8815-25. [PMID: 29806703 DOI: 10.1002/jcp.26795] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
14 Stelmach E, Masiak J. Case Report: Psychopathological Syndromes in the Course of Lupus Erythematosus and the Co-occurrence of Lupus Erythematous With Mental Disorders. Front Psychiatry 2021;12:668050. [PMID: 34248705 DOI: 10.3389/fpsyt.2021.668050] [Reference Citation Analysis]
15 Jiang J, Zhao M, Chang C, Wu H, Lu Q. Type I Interferons in the Pathogenesis and Treatment of Autoimmune Diseases. Clin Rev Allergy Immunol 2020;59:248-72. [PMID: 32557263 DOI: 10.1007/s12016-020-08798-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 16.0] [Reference Citation Analysis]
16 Khalid Rafat W, Sarmast ST, Shiza ST, Olaleye K, Rogers S. Posterior Reversible Encephalopathy in Undiagnosed Systemic Lupus Erythematosus: A Rare Case Report. Cureus 2021;13:e16945. [PMID: 34513513 DOI: 10.7759/cureus.16945] [Reference Citation Analysis]
17 Günther S, Fagone P, Jalce G, Atanasov AG, Guignabert C, Nicoletti F. Role of MIF and D-DT in immune-inflammatory, autoimmune, and chronic respiratory diseases: from pathogenic factors to therapeutic targets. Drug Discov Today 2019;24:428-39. [PMID: 30439447 DOI: 10.1016/j.drudis.2018.11.003] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 10.8] [Reference Citation Analysis]
18 Zhou Z, You Y, Wang F, Sun Y, Teng J, Liu H, Cheng X, Su Y, Shi H, Hu Q, Chi H, Jia J, Wan L, Liu T, Wang M, Shi C, Yang C, Ye J. Urine Proteomics Differentiate Primary Thrombotic Antiphospholipid Syndrome From Obstetric Antiphospholipid Syndrome. Front Immunol 2021;12:702425. [PMID: 34489952 DOI: 10.3389/fimmu.2021.702425] [Reference Citation Analysis]
19 Liang F, Qin W, Zeng Y, Wang D. Modulation of Autoimmune and Autoinflammatory Diseases by Gasdermins. Front Immunol 2022;13:841729. [PMID: 35720396 DOI: 10.3389/fimmu.2022.841729] [Reference Citation Analysis]
20 Sciascia S, Radin M, Roccatello D, Sanna G, Bertolaccini ML. Recent advances in the management of systemic lupus erythematosus. F1000Res 2018;7:F1000 Faculty Rev-970. [PMID: 30026918 DOI: 10.12688/f1000research.13941.1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.8] [Reference Citation Analysis]
21 Fioredda F, Cappelli E, Mariani A, Beccaria A, Palmisani E, Grossi A, Ceccherini I, Venè R, Micalizzi C, Calvillo M, Pierri F, Mancini I, Peyvandi F, Corsolini F, Dufour C, Miano M. Thrombotic thrombocytopenic purpura and defective apoptosis due to CASP8/10 mutations: the role of mycophenolate mofetil. Blood Adv 2019;3:3432-5. [PMID: 31714957 DOI: 10.1182/bloodadvances.2019000575] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Morand EF, Mosca M. Treat to target, remission and low disease activity in SLE. Best Practice & Research Clinical Rheumatology 2017;31:342-50. [DOI: 10.1016/j.berh.2017.09.009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
23 Canedo-Marroquín G, Saavedra F, Andrade CA, Berrios RV, Rodríguez-Guilarte L, Opazo MC, Riedel CA, Kalergis AM. SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatments. Front Immunol 2020;11:569760. [PMID: 33362758 DOI: 10.3389/fimmu.2020.569760] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
24 Fante MA, Holler B, Weber D, Angstwurm K, Bergler T, Holler E, Edinger M, Herr W, Wertheimer T, Wolff D. Cyclophosphamide for salvage therapy of chronic graft-versus-host disease: a retrospective analysis. Ann Hematol 2020;99:2181-90. [PMID: 32715339 DOI: 10.1007/s00277-020-04193-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
25 Xiong ZH, Cao XS, Guan HL, Zheng HL. Immunotherapies application in active stage of systemic lupus erythematosus in pregnancy: A case report and review of literature. World J Clin Cases 2020; 8(24): 6396-6407 [PMID: 33392323 DOI: 10.12998/wjcc.v8.i24.6396] [Reference Citation Analysis]
26 Talotta R, Atzeni F, Laska MJ. Therapeutic peptides for the treatment of systemic lupus erythematosus: a place in therapy. Expert Opin Investig Drugs 2020;29:845-67. [PMID: 32500750 DOI: 10.1080/13543784.2020.1777983] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]